Fig. 4
From: In vivo guiding nitrogen-doped carbon nanozyme for tumor catalytic therapy
Tumor therapy based on N-PCNSs using HFn coordination. a Schematic for N-PCNSs induced tumor cell destruction via ferritin-mediated specific delivery. b TEM image of HFn assembled onto N-PCNSs. Scale bar: 50 nm. c TEM image of cancer cells treated with HFn-PCNSs. Red arrows indicate the position of HFn-PCNSs. Scale bar: 500 nm. d Quantification of HFn-enhanced internalization of N-PCNSs by flow cytometry analysis (n = 3). Statistical significance is assessed by unpaired Student’s two-sided t-test compared to the control group. ****p < 0.0001. e Tumor morphology and progress with HFn-N-PCNSs treatment (n = 5). f Accumulation of N-PCNSs in tumors. White arrow: edge of the tumor area. Scale bar: 200 µm. g Tumor volume after i.t. treatment with HFn-N-PCNSs (n = 5). h Survival results of tumor therapy with HFn-N-PCNSs i.t. treatment (n = 5). Asterisks indicate ****p < 0.0001 for HFn-N-PCNSs-3 group compared with control groups (Kaplan–Meier). i Tumor volume after i.v. treatment with HFn-N-PCNSs (n = 5). Statistical significance is assessed by unpaired Student’s two-sided t-test compared to the control groups. ***p < 0.001. j Body weight changes of treated mice following i.v. injection of HFn-N-PCNSs (n = 5). Mean values and error bars are defined as mean and s.d., respectively. i.t. intratumorally, i.v. intravenously
